NDAORALTABLET
Approved
Mar 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ZIAC (bisoprolol fumarate and hydrochlorothiazide) by Teva is clinical pharmacology bisoprolol fumarate and hctz have been used individually and in combination for the treatment of hypertension. Approved for the management of hypertension. First approved in 1993.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZIAC is a fixed-dose combination tablet containing bisoprolol fumarate (a cardioselective beta-1 blocker) and hydrochlorothiazide (a thiazide diuretic) approved for hypertension management. The two agents work synergistically: bisoprolol provides beta-adrenergic blockade while HCTZ enhances sodium/chloride excretion, with additive antihypertensive effects. The low-dose HCTZ formulation (6.25 mg) significantly reduces hypokalemia risk compared to higher diuretic doses.
$0.112MPart D
LOE ApproachingDeclining
Mature product with minimal commercial growth; sales and marketing teams are likely lean or being redirected to newer franchises.
Mechanism of Action
CLINICAL PHARMACOLOGY Bisoprolol fumarate and HCTZ have been used individually and in combination for the treatment of hypertension. The antihypertensive effects of these agents are additive; HCTZ 6.25 mg significantly increases the antihypertensive effect of bisoprolol fumarate. The incidence of…
Worked on ZIAC at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.